The financing round was led by Soulmates Ventures with backing from several new and existing investors.
"Antiverse is tackling one of the most technically demanding problems in drug discovery. The team’s ability to reduce the development time for de novo therapeutic-grade antibodies in a defined domain to under four months is a significant scientific and operational achievement. This capability, combined with the AI-driven design and in-house labs, positions Antiverse on track to become a global leader and the go-to developer of antibody therapies for the most elusive disease targets in medicine"
ARIA led a £16m grant to establish a new inference lab for AI scale-ups.
"The Scaling Inference Lab creates a practical environment where new AI infrastructure can be tested and proven at system scale. It builds on CommonAI’s vision of shared infrastructure, allowing organisations to innovate without needing the scale or resources of large technology providers. By improving access to efficient, trusted computing platforms, we can help create a more accessible AI ecosystem and unlock greater economic opportunity across the UK."
The Cambridge-born startup secured backing to scale its software stack and expand its London team.
"Big labs are currently betting that one model will rule them all. We think that’s wrong and our work proves this. Nature shows that real intelligence emerges from many systems working together. We’ve brought together incredible talent to enable a paradigm shift in how we build intelligent systems to solve real-world problems, with the infrastructure to make that possible, on any chip, anywhere in the world."
Wellington Management led the financing round, which brings total funding to £110m.
"Everyone is focused on building bigger models, but for physical AI, the bottleneck isn't model size. It's data readiness. You can have the most sophisticated model in the world, and it will still fail if the data feeding it is incomplete, inconsistent, or misaligned with real-world conditions. That's the problem we solve."
The funding will support Phase I clinical trials for the company lead antimicrobial candidate.
"We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset. I would like to thank the AMR Action Fund, as well as all of our existing investors and collaborators, for their support."
.png)
